Company Insights

HROW customer relationships

Explore interactive graphBrowse insights index
HROW customer relationship map

Harrow Health (HROW) — customer relationships that drive revenue and risk

Harrow Health is an ophthalmology-focused commercial platform that monetizes through three primary channels: branded ophthalmic product sales to wholesalers and providers, specialty pharmacy and compounding pharmacy services, and licensing/royalty arrangements. Revenue recognition mixes direct product sales, cash-pay compounded formulations, and recurring royalties — a structure that amplifies upside when coverage expands but concentrates exposure to a small set of major payors and distribution partners. Read deeper or explore relationship signals on Null Exposure: https://nullexposure.com/

What the commercial model looks like in practice

Harrow’s monetization is built around selling prescription and OTC eye-care products at scale through wholesalers and an owned compounding business (ImprimisRx), while simultaneously extracting licensing and royalty income from out-licensed assets. Key commercial characteristics derived from company disclosures and filings:

  • Contracting posture: a mix of short-term transactional sales (compounded and retail cash-pay), licensing arrangements with multi-year royalty mechanics, and participation in public pricing programs (FSS, Medicaid/Medicare reporting). The company’s public filings identify short measurement periods for pass-through reimbursement and no significant financing components, supporting a largely near-term cash conversion profile.
  • Counterparty concentration and criticality: government payors and a small number of large distributors dominate the economics; Harrow discloses accounts receivable concentration where two customers accounted for ~94% of AR at year-end 2024, flagging a single-point-of-failure risk.
  • Revenue mix and maturity: branded product sales are the core segment, supplemented by ImprimisRx compounding services (cash-pay and prescriber-driven), and licensing royalties — a hybrid that blends mature product cash flows with higher-margin, but more variable, services revenue.
  • Geography and regulatory exposure: operations and sales are U.S.-centric, with regulatory and reimbursement dynamics (Medicare/Medicaid, IRA-driven Part D reforms) materially shaping coverage and price.

These characteristics collectively make Harrow a commercial-stage specialty-pharma operator with material reliance on distribution partners, government reimbursement pathways, and a handful of large customers.

Who Harrow does business with — relationship-by-relationship

Below are the relationships surfaced in public calls and news, each summarized in plain English with source context.

Apollo Care

Harrow added Apollo Care to its specialty pharmacy network in Q4 2025 to increase covered access to VEVYE; management cited this addition as part of improved coverage expected to boost patient access. (2025 Q3 earnings call)

PhilRx

PhilRx is Harrow’s national mail-order specialty pharmacy partner and was handling all VEVYE prescriptions in Q3 2025, later serving as a primary channel for the VEVYE Access program; Harrow uses PhilRx as a gateway to broaden patient access nationwide. (Glance EyesOnEyecare, March 2025; 2025 Q3 earnings call)

Apexus, LLC

Harrow secured a 340B Prime Vendor Program arrangement via Apexus that makes IHEEZO and other Harrow products accessible under federal 340B pricing — a strategic distribution and reimbursement milestone with FY2026 reporting. (Glance EyesOnEyecare, July 2024 / reported as FY2026)

GoodRx

Harrow partnered with GoodRx to provide cash-pay alternatives for a basket of Harrow products (including VEVYE and others), expanding affordability and alternate channels outside traditional payer reimbursement in FY2024. (ModernRetina, reported FY2024)

Centers for Medicare & Medicaid Services (CMS)

CMS granted transitional pass-through reimbursement for TRIESENCE at ASP+6% for ASC and HOPD settings, directly improving reimbursement mechanics for that product in FY2025. (BioSpace press release, FY2025)

CVS

CVS communicated formulary positioning for VEVYE to eyecare professionals, indicative of PBM formulary influence; management highlighted CVS outreach as part of coverage gains for VEVYE in FY2026. (Earnings call transcript coverage, InsiderMonkey, FY2026)

Cencora (AmerisourceBergen)

Cencora is listed among wholesale distributors providing direct availability for Harrow products, forming part of the primary distributor network supporting branded sales in FY2025. (Glance EyesOnEyecare, March 2025)

McKesson

McKesson is one of the major wholesale distributors cited as directly distributing Harrow’s branded products, a critical channel for national product availability in FY2025. (Glance EyesOnEyecare, March 2025)

ImprimisRx

ImprimisRx is Harrow’s compounding/pharmacy business and a material revenue contributor; management noted a one-time revenue headwind from ImprimisRx activity in 2025 guidance but described the issue as resolved and underlying trends intact. (Finviz summary of FY2026 commentary)

iOR Partners

Harrow expanded a national product supply agreement with iOR Partners — a supplier to office-based cataract surgery providers — reinforcing the company’s route-to-clinic distribution footprint (announced FY2022). (Glance EyesOnEyecare, December 2022)

Alto (AltoRx)

Alto joined Harrow’s specialty pharmacy network in late 2025 alongside Apollo Care, further broadening specialty fulfillment and expected to increase covered therapy uptake for VEVYE. (2025 Q3 earnings call)

Cardinal (Cardinal Health)

Cardinal is named among the major wholesale distributors (with McKesson and Cencora) that provide direct product availability and channel reach for Harrow’s branded portfolio in FY2025. (Glance EyesOnEyecare, March 2025)

What these relationships imply for investors and operators

  • Distribution is concentrated but comprehensive. Harrow sells through the three large wholesalers (McKesson, Cardinal, Cencora) and supplements reach with specialty pharmacies (PhilRx, Apollo Care, Alto) and cash channels (GoodRx). This multi-channel approach supports growth but places outsized operational importance on a few counterparties.
  • Government pricing and reimbursement shape unit economics. CMS decisions (pass-through status) and 340B access via Apexus materially change payer reimbursement and net realized price; policy shifts are direct earnings levers.
  • Customer concentration is an operational risk. The company’s disclosures that two customers comprised ~94% of accounts receivable in 2024 is a signal of single-counterparty exposure that investors must stress-test.
  • Licensing and compounding add optionality — and regulatory complexity. Licensing provides recurring royalty upside; ImprimisRx and 503B manufacturing offer margin expansion but demand rigorous regulatory controls and limit anticipatory scaling under 503A rules.

If you want a deeper, annotated map of these customer signals for due diligence, visit https://nullexposure.com/ for access and analyst tools.

Bottom line and recommended next steps

Harrow is a commercialization-oriented ophthalmics platform with a clear monetization mix: branded product sales, compounding/pharmacy services, and licensing royalties. That structure delivers scaled revenue but exposes the company to high counterparty concentration, government reimbursement sensitivity, and distributor dependence. For investors, primary diligence should focus on receivables concentration remediation, the durability of specialty pharmacy contracts (PhilRx/Apollo/Alto), and the company’s management of regulatory risk at its compounding facilities.

To explore the relationship signals and make them actionable for investment or operations, see Null Exposure’s coverage: https://nullexposure.com/

Key next steps for operators and investors: validate AR concentration reduction plans, track PBM/formulary placements (e.g., CVS), and monitor execution on specialty pharmacy rollouts that materially affect patient access and realized revenue.